Evidence map›Paper›PMID 26530628›Full record

ArticleSchizophrenia research2015

Modeling the role of negative symptoms in determining social functioning in individuals at clinical high risk of psychosis.

Danielle A Schlosser, Timothy R Campellone, Bruno Biagianti, Kevin L Delucchi, David E Gard, Daniel Fulford, Barbara K Stuart, Melissa Fisher, Rachel L Loewy, Sophia Vinogradov

Abstract read
In one paragraph

Article in Schizophrenia research, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
46citing papers in PubMed, 4 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

46 citing papers in PubMed, 4 syntheses or guidelines pooled it.

  1. Pooled it
  2. EPA guidance on assessment of negative symptoms in schizophrenia.European psychiatry : the journal of the Association of European Psychiatrists · 2021
    Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Danielle A SchlosserUniversity of California at San Francisco, United States. Electronic address: Danielle.schlosser@ucsf.edu.
Timothy R CampelloneUniversity of California at San Francisco, United States; University of California at Berkeley, United States.
Bruno BiagiantiUniversity of California at San Francisco, United States.
Kevin L DelucchiUniversity of California at San Francisco, United States.
David E GardSan Francisco State University, United States.
Daniel FulfordBoston University, United States.
Barbara K StuartUniversity of California at San Francisco, United States.
Melissa FisherUniversity of California at San Francisco, United States; San Francisco Veterans Affairs Medical Center, United States.
Rachel L LoewyUniversity of California at San Francisco, United States.
Sophia VinogradovUniversity of California at San Francisco, United States; San Francisco Veterans Affairs Medical Center, United States.

Funding

Neuroscience-Guided Cognitive Remediation in Adolescents at Risk for PsychosisR01MH081051 · NIMH · NORTHERN CALIFORNIA INSTITUTE/RES/EDU · PI VINOGRADOV, SOPHIA · 2008 to 2012
$2.4M
Enhancing Functional Outcomes in Schizophrenia Using a Novel mHealth ApproachR34MH100399 · NIMH · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI ANGUERA, JOAQUIN A, VINOGRADOV, SOPHIA · 2013 to 2015
$710k
PRIME to Action: Enhancing Motivation in Recent Onset SchizophreniaK23MH097795 · NIMH · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI SCHLOSSER, DANIELLE A. · 2013 to 2016
$704k
NIMH NIH HHS K23 MH097795NIMH NIH HHS K23 MH097795-01NIMH NIH HHS R01 01MH081051NIMH NIH HHS R01 MH081051NIMH NIH HHS R34 MH100399
6 · The paper itself

Abstract

A priority for improving outcome in individuals at clinical high risk (CHR) is enhancing our understanding of predictors of psychosis as well as psychosocial functioning. Social functioning, in particular, is a unique indicator of risk as well as an important outcome in itself. Negative symptoms are a significant determinant of social functioning in CHR individuals; yet, it is unclear which specific negative symptoms drive functional outcome and how these symptoms function relative to other predictors, such as neurocognition and mood/anxiety symptoms. In a sample of 85 CHR individuals, we examined whether a two-factor negative symptom structure that is found in schizophrenia (experiential vs expressive symptoms) would be replicated in a CHR sample; and tested the degree to which specific negative symptoms predict social functioning, relative to neurocognition and mood/anxiety symptoms, which are known to predict functioning. The two-factor negative symptom solution was replicated in this CHR sample. Negative symptom severity was found to be uniquely predictive of social functioning, above and beyond depression/anxiety and neurocognition. Experiential symptoms were more strongly associated with social functioning, relative to expression symptoms. In addition, experiential symptoms mediated the relationship between expressive negative symptoms and social functioning. These results suggest that experiences of motivational impairment are more important in determining social functioning, relative to affective flattening and alogia, in CHR individuals, thereby informing the development of more precise therapeutic targets. Developing novel interventions that stimulate goal-directed behavior and reinforce rewarding experiences in social contexts are recommended.

Indexed as

Prodromal SymptomsSocial AdjustmentAdolescentFemaleHumansMalePsychotic DisordersRisk FactorsSocial Behavior DisordersStatistics as TopicYoung AdultExperiential negative symptomsExpressive negative symptomsMotivationProdromalPsychosisSocial functioning

Identifiers

PMID26530628
PMCPMC4681660

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.